Otsuka Pharmaceutical Co Ltd has reached an agreement to acquire Astex Pharmaceuticals Inc, which has an oncology portfolio as well as fragment-based drug discovery technology. The deal is valued at $866 million.
Acacia Pharma Ltd has raised £15 million in a Series B financing from a group led by Fidelity Biosciences and Novo A/S in order to complete Phase 3 development of one cancer supportive care product, and advance development of two others.
The Biotechnology Value Fund (BVF) LP of the US and affiliates have invested €30 million via a share placement in Evotec AG and taken out an option to buy a further stake from an existing shareholder, which could raise the holding to more than 18%.
AstraZeneca Plc said that its biologics arm, MedImmune, has reached agreement to acquire privately-held Amplimmune of Maryland, US in a move that will strengthen its portfolio of immune-mediated cancer therapies.
Amgen Inc has reach agreement to take over Onyx Pharmaceuticals Inc for $10.4 billion in cash thereby strengthening its oncology portfolio and acquiring a marketed product for multiple myeloma. The agreement was announced on Sunday.
Addex Therapeutics Ltd has raised gross proceeds of CHF 3.2 million ($3.5 million) in a private placement of shares enabling it continue operations beyond its next important clinical event – the reporting of data from a study in anxious depression.
GlaxoSmithKline Plc has launched a new $50 million venture capital fund in Cambridge, Massachusetts, US that will invest in companies working in the field of bioelectronic medicine. The term ‘bioelectronic medicine’ refers to non-pharmaceutical interventions that seek to treat disease by changing or directing electrical signals in the body.
The Medicines Company of the US has completed the acquisition of ProFibrix BV following the successful completion of a Phase 3 trial of the Dutch company’s hospital product – a sealant to stop bleeding during and after surgery.
Bayer Healthcare has announced a new oncology collaboration and licensing agreement with Compugen Ltd to research and develop antibody-based therapeutics in oncology against two novel targets. The deal is valued at more than $500 million.
Actelion Ltd is set to acquire Ceptaris Therapeutics Inc of the US pending Food and Drug Administration approval of that company’s product for mycosis fungoides, a rare form of non-Hodgkin’s lymphoma. The upfront payment is $25 million.